Israel’s UB-Therapeutics is developing a novel therapy for the treatment of multiple myeloma. Its proteasome degradation inhibitor is a cyclic peptide that directly targets the degradation pathway of the proteasome – overcoming cancer’s resistance to existing proteasome inhibitors.
https://ats.org/our-impact/fighting-cancer-drug-resistance/